Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast Cancer

Video

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting.

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.

Related Videos
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store- Image credit: C Daniels/peopleimages.com | stock.adobe.com
View in microscopic of pathology cross section tissue ductal cell carcinoma or adenocarcinoma diagnosis by pathologist in laboratory | Image Credit: arcyto - stock.adobe.com
A female doctor sits at her desk and talks to a female patient while looking at her mammogram | Image Credit: lordn - stock.adobe.com
Doctor holding a digital tablet with x-ray of brain and skull skeleton. Headache, meningitis and migraine concept - Image credit: Steph photographies | stock.adobe.com
Woman Physician Talking With Her Patient | Image Credit: LStockStudio - stock.adobe.com
A health visitor explaining a senior woman how to take pills - Image credit: Halfpoint | stock.adobe.com
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Related Content
Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer

Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer

December 7th 2023
Article
Independent Rx Forum: NCPA Priorities, Legislative Updates for Independent Pharmacies

Independent Rx Forum: NCPA Priorities, Legislative Updates for Independent Pharmacies

November 28th 2023
Podcast
Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer

Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer

December 7th 2023
Article
Independent Rx Forum - NCPA Conference: Legal Update on PBM Litigation

Independent Rx Forum - NCPA Conference: Legal Update on PBM Litigation

October 24th 2023
Podcast
Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab

Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab

December 6th 2023
Article
Close up view of doctor touching patient hand, showing empty and kindness - Image credit: Bongkarn | stock.adobe.com

Expert Discusses A Health System Specialty Pharmacy Initiative: Abemaciclib Linkage to Care

December 6th 2023
Article
© 2023 MJH Life Sciences

All rights reserved.